Trial reportAlzheimer's & dementia : the journal of the Alzheimer's Association2013
Risk disclosure and preclinical Alzheimer's disease clinical trial enrollment.
Trial report in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Examining the Role of Community Engagement in Enhancing the Participation of Racial and Ethnic Minoritized Communities in Alzheimer's Disease Clinical Trials; A Rapid Review.The journal of prevention of Alzheimer's disease · 2024Pooled it
- The Value of Pre-Screening in the Alzheimer's Prevention Initiative (API) Autosomal Dominant Alzheimer's Disease Trial.The journal of prevention of Alzheimer's disease · 2018Trial
- Feasibility and acceptability of remote APOE-genotyping among research volunteers of an online recruitment registry (The Dutch Brain Research Registry).The journal of prevention of Alzheimer's disease · 2025Article
- A qualitative study on the impact and participation in the AGELESS multidomain intervention: Insights from older adults with cognitive frailty and their caregivers.BMC public health · 2025Article
- Recruitment of pre-dementia participants: main enrollment barriers in a longitudinal amyloid-PET study.Alzheimer's research & therapy · 2023Observational
- US Adults' Likelihood to Participate in Dementia Prevention Drug Trials: Results from the National Poll on Healthy Aging.The journal of prevention of Alzheimer's disease · 2023Article
- Experiences of Participation in a Multimodal Preventive Trial MIND-ADJournal of multidisciplinary healthcare · 2022Article
- Reasons for undergoing amyloid imaging among cognitively unimpaired older adults.Annals of clinical and translational neurology · 2021Article
- Communicating 5-Year Risk of Alzheimer's Disease Dementia: Development and Evaluation of Materials that Incorporate Multiple Genetic and Biomarker Research Results.Journal of Alzheimer's disease : JAD · 2021Article
- Barriers to Participation in Therapeutic Clinical Trials as Perceived by Community Oncologists.JCO oncology practice · 2020Article
- "From Victimhood to Warriors": Super-researchers' Insights Into Alzheimer's Disease Clinical Trial Participation Motivations.The Gerontologist · 2020Article
- Experiences of dementia and attitude towards prevention: a qualitative study among older adults participating in a prevention trial.BMC geriatrics · 2020Article
- Attitudes of Potential Participants Towards Molecular Therapy Trials in Huntington's Disease.Journal of Huntington's disease · 2019Article
- Motivators for Alzheimer's disease clinical trial participation.Aging clinical and experimental research · 2018Article
- Attitudes toward clinical trials across the Alzheimer's disease spectrum.Alzheimer's research & therapy · 2017Article
- Recruiting to preclinical Alzheimer's disease clinical trials through registries.Alzheimer's & dementia (New York, N. Y.) · 2017Article
- Primary and Secondary Prevention Trials in Alzheimer Disease: Looking Back, Moving Forward.Current Alzheimer research · 2017Review
- Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2016Review
- Disclosure of amyloid status is not a barrier to recruitment in preclinical Alzheimer's disease clinical trials.Neurobiology of aging · 2016Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
To identify the facilitators and barriers to preclinical Alzheimer's disease (AD) clinical trial recruitment, 50 cognitively normal participants were interviewed after being randomized to one of two hypothetical AD risk scenarios: (1) the general age-related risk for AD, or (2) being at 50% increased risk for AD. Participants provided uncued barriers and facilitators to the hypothetical decision of whether they would enroll. Thirteen themes of facilitators and five themes of barriers were identified. The most common barrier was fear related to taking study drug. Those randomized to being at increased risk for AD more frequently cited lowering personal risk as a facilitator (P = .01) and less frequently cited time as a barrier to enrollment (P = .02). These results suggest potential challenges to preclinical AD clinical trial recruitment and that disclosing risk information may enhance enrollment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.